NASDAQ : APGE
Apogee Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 135.07 USD (Sep 3, 2026, 4:00 PM EDT) · Market cap 10.19B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 83.01M | 70.88M | 49.01M | 24.58M | 3.21M |
| Research & Development | 240.74M | 214.71M | 167.87M | 68.42M | 30.31M |
| Operating Expenses | 323.75M | 285.60M | 216.87M | 93.00M | 33.52M |
| Operating Income | -323.75M | -285.60M | -216.87M | -93.00M | -33.52M |
| Interest & Investment Income | 35.60M | 30.03M | 34.74M | 9.02M | 100.36K |
| Other Non Operating Income (Expenses) | -9.98M | ||||
| Pretax Income | -294.09M | -255.56M | -182.13M | -83.98M | -43.40M |
| Income Tax Expense | 280.00K | 278.00K | 18.00K | ||
| Net Income | -294.37M | -255.84M | -182.15M | -83.98M | -43.40M |
| Net Income to Common | -294.37M | -255.84M | -182.15M | -83.98M | -43.40M |
| Shares Outstanding (Basic) | 67.82M | 60.69M | 55.19M | 25.01M | 2.46M |
| Shares Outstanding (Diluted) | 67.82M | 60.69M | 55.19M | 25.01M | 2.46M |
| EPS (Basic) | -4.34 | -4.22 | -3.30 | -3.36 | -17.63 |
| EPS (Diluted) | -4.34 | -4.22 | -3.30 | -3.36 | -17.63 |
| Free Cash Flow | -243.96M | -232.60M | -172.33M | -74.93M | -17.92M |
| Free Cash Flow Per Share | -3.60 | -3.83 | -3.12 | -3.00 | -7.28 |
| EBITDA | -322.12M | -284.18M | -216.68M | ||
| D&A For EBITDA | 1.63M | 1.42M | 189.00K | ||
| EBIT | -323.75M | -285.60M | -216.87M | -93.00M | -33.52M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 105.57M | 131.55M | 141.79M | 118.32M | 151.89M |
| Short-Term Investments | 866.36M | 598.64M | 378.86M | 277.14M | |
| Cash & Short-Term Investments | 971.93M | 730.19M | 520.65M | 395.46M | 151.89M |
| Other Receivables | 9.59M | 5.96M | 4.70M | 1.21M | |
| Receivables | 9.59M | 5.96M | 4.70M | 1.21M | |
| Prepaid Expenses | 8.78M | 4.60M | 2.62M | 1.74M | 108.00K |
| Other Current Assets | 1.44M | 605.00K | 1.74M | 57.00K | |
| Total Current Assets | 991.73M | 741.36M | 529.71M | 398.41M | 152.06M |
| Property, Plant & Equipment | 11.53M | 14.38M | 13.32M | 2.59M | |
| Long-Term Investments | 321.94M | 172.73M | 210.42M | ||
| Other Long-Term Assets | 10.61M | 8.67M | 498.00K | 401.00K | |
| Total Assets | 1.34B | 937.13M | 753.95M | 401.40M | 152.06M |
| Accounts Payable | 3.08M | 1.22M | 1.07M | 2.14M | 418.00K |
| Accrued Expenses | 32.06M | 23.18M | 24.25M | 17.31M | 9.56M |
| Current Portion of Leases | 2.37M | 3.50M | 3.23M | 1.10M | |
| Total Current Liabilities | 37.51M | 27.91M | 28.56M | 20.56M | 9.98M |
| Long-Term Leases | 4.47M | 5.34M | 8.60M | 933.00K | |
| Total Liabilities | 141.21M | 33.25M | 37.16M | 21.49M | 9.98M |
| Common Stock | 1.00K | 1.00K | 1.00K | 2.25M | |
| Additional Paid-In Capital | 1.92B | 1.46B | 1.02B | 503.35M | |
| Retained Earnings | -721.72M | -561.76M | -305.92M | -123.77M | -39.78M |
| Comprehensive Income & Other | -2.50M | 1.08M | 915.00K | 329.00K | 2.14M |
| Total Common Equity | 1.19B | 903.88M | 716.79M | 379.91M | -35.39M |
| Shareholders' Equity | 1.19B | 903.88M | 716.79M | 379.91M | 142.07M |
| Total Liabilities & Equity | 1.34B | 937.13M | 753.95M | 401.40M | 152.06M |
| Total Debt | 6.83M | 8.85M | 11.83M | 2.03M | |
| Net Cash (Debt) | 1.29B | 894.07M | 719.24M | 393.43M | 151.89M |
| Net Cash Per Share | 18.98 | 14.73 | 13.03 | 15.73 | 61.69 |
| Filing Date Shares Outstanding | 75.42M | 68.85M | 58.09M | 48.52M | 5.00M |
| Total Common Shares Outstanding | 75.07M | 68.40M | 58.06M | 48.52M | 5.00M |
| Working Capital | 954.22M | 713.45M | 501.15M | 377.85M | 142.07M |
| Book Value Per Share | 15.91 | 13.21 | 12.35 | 7.83 | -7.08 |
| Tangible Book Value | 1.19B | 903.88M | 716.79M | 379.91M | -35.39M |
| Tangible Book Value Per Share | 15.91 | 13.21 | 12.35 | 7.83 | -7.08 |
| Machinery | 4.13M | 4.22M | 1.28M | ||
| Leasehold Improvements | 3.08M | 3.08M | 863.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -294.37M | -255.84M | -182.15M | -83.98M | -43.40M |
| Depreciation & Amortization | 1.63M | 1.42M | 189.00K | ||
| Loss (Gain) From Sale of Investments | -6.65M | -7.50M | -12.24M | -3.07M | |
| Stock-Based Compensation | 57.62M | 46.28M | 23.33M | 6.10M | 2.34M |
| Other Operating Activities | 5.46M | 3.68M | 1.69M | 87.00K | 12.44M |
| Change in Accounts Payable | -2.60M | 150.00K | -1.07M | 1.61M | 456.00K |
| Change in Other Net Operating Assets | -5.03M | -15.63M | -930.00K | 4.49M | 10.25M |
| Operating Cash Flow | -243.89M | -227.45M | -171.17M | -74.76M | -17.92M |
| Capital Expenditures | -62.00K | -5.15M | -1.15M | -167.00K | |
| Investment in Securities | -687.84M | -174.43M | -299.31M | -273.74M | |
| Investing Cash Flow | -687.89M | -179.57M | -300.46M | -273.91M | |
| Issuance of Common Stock | 815.12M | 396.49M | 495.11M | 315.39M | |
| Other Financing Activities | 97.75M | -745.09K | |||
| Financing Cash Flow | 912.87M | 396.49M | 495.11M | 315.39M | 183.62M |
| Net Cash Flow | -18.91M | -10.53M | 23.47M | -33.28M | 165.70M |
| Free Cash Flow | -243.96M | -232.60M | -172.33M | -74.93M | -17.92M |
| Free Cash Flow Per Share | -3.60 | -3.83 | -3.12 | -3.00 | -7.28 |
| Levered Free Cash Flow | -145.62M | -138.98M | -113.42M | -45.50M | |
| Unlevered Free Cash Flow | -144.64M | -138.98M | -113.42M | -45.50M | |
| Change in Working Capital | -7.62M | -15.48M | -2.00M | 6.11M | 10.71M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 10.19B | 5.09B | 2.58B | 1.34B | |
| Enterprise Value | 8.90B | 4.51B | 1.84B | 918.76M | |
| Last Close Price | 135.07 | 75.48 | 45.30 | 27.94 | |
| PB Ratio | 8.49 | 5.64 | 3.60 | 3.53 | |
| P/TBV Ratio | 8.53 | 5.64 | 3.60 | 3.53 | |
| Debt / Equity Ratio | 0.01 | 0.01 | 0.02 | 0.01 | |
| Net Debt / Equity Ratio | -1.08 | -0.99 | -1.00 | -1.04 | -1.07 |
| Net Debt / EBITDA Ratio | 4.00 | 3.15 | 3.32 | ||
| Net Debt / FCF Ratio | 5.28 | 3.84 | 4.17 | 5.25 | 8.48 |
| Quick Ratio | 26.17 | 26.38 | 18.39 | 19.30 | 15.22 |
| Current Ratio | 26.44 | 26.57 | 18.55 | 19.38 | 15.24 |
| Return on Equity (ROE) | -32.45% | -31.57% | -33.22% | -32.18% | |
| Return on Assets (ROA) | -20.30% | -21.11% | -23.46% | -21.00% | |
| Return on Capital Employed (ROCE) | -24.90% | -31.40% | -29.90% | -24.40% | -23.60% |
| Earnings Yield | -2.89% | -5.02% | -7.07% | -6.26% | |
| FCF Yield | -2.39% | -4.57% | -6.69% | -5.58% | |
| Buyback Yield / Dilution | -17.59% | -9.96% | -120.72% | -915.57% |